The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides Seite 1

28.11.2023 - SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the 'Company'), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the ... Seite 1

Related Keywords

India , ,Karveer Meditech ,Adverse Events Found ,Healthy Volunteers Cohorts ,Single Ascending Dose ,Multiple Ascending Dose ,Multiple Ascending Dose Clinical Trial ,Healthy Volunteers Was Completed ,Executive Chairman ,